185 related articles for article (PubMed ID: 15928668)
1. Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients.
Tonini G; Vincenzi B; Santini D; Scarpa S; Vasaturo T; Malacrino C; Coppola R; Magistrelli P; Borzomati D; Baldi A; Antinori A; Caricato M; Nuzzo G; Picciocchi A
Br J Cancer; 2005 Jun; 92(12):2225-32. PubMed ID: 15928668
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients.
Santini D; Vincenzi B; Tonini G; Scarpa S; Vasaturo F; Malacrino C; Vecchio F; Borzomati D; Valeri S; Coppola R; Magistrelli P; Nuzzo G; Picciocchi A
Clin Cancer Res; 2005 May; 11(10):3784-9. PubMed ID: 15897577
[TBL] [Abstract][Full Text] [Related]
3. High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma.
Zhou L; Lu J; Liang ZY; Zhou WX; Yuan D; Li BQ; You L; Guo JC; Zhao YP
J Surg Oncol; 2018 Dec; 118(7):1115-1121. PubMed ID: 30261114
[TBL] [Abstract][Full Text] [Related]
4. The combination of strong immunohistochemical mtTFA expression and a high survivin index predicts a shorter disease-specific survival in pancreatic ductal adenocarcinoma.
Kimura T; Kitada S; Uramoto H; Zhi L; Kawatsu Y; Takeda T; Horie S; Nabeshima A; Noguchi H; Sasaguri Y; Izumi H; Kohno K; Yamada S
Histol Histopathol; 2015 Feb; 30(2):193-204. PubMed ID: 25108120
[TBL] [Abstract][Full Text] [Related]
5. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma.
Ueda S; Ogata S; Tsuda H; Kawarabayashi N; Kimura M; Sugiura Y; Tamai S; Matsubara O; Hatsuse K; Mochizuki H
Pancreas; 2004 Jul; 29(1):e1-8. PubMed ID: 15211117
[TBL] [Abstract][Full Text] [Related]
6. Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma.
Bhanot U; Heydrich R; Möller P; Hasel C
Am J Surg Pathol; 2006 Jun; 30(6):754-9. PubMed ID: 16723855
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of survivin in pancreatic endocrine tumors.
Ekeblad S; Lejonklou MH; Stålberg P; Skogseid B
World J Surg; 2012 Jun; 36(6):1411-8. PubMed ID: 22089920
[TBL] [Abstract][Full Text] [Related]
8. MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients.
Pantano F; Baldi A; Santini D; Vincenzi B; Borzomati D; Vecchio FM; Castri F; Antinori A; Caraglia M; Magistrelli P; Coppola R; Tonini G
Cancer Biol Ther; 2009 Jun; 8(11):996-9. PubMed ID: 19587537
[TBL] [Abstract][Full Text] [Related]
9. The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma.
Sagol O; Yavuzsen T; Oztop I; Ulukus C; Ylmaz U; Alakavuklar M; Karademir S; Obuz F; Astarcoğlu H; Astarcoglu I
Pancreas; 2005 May; 30(4):343-8. PubMed ID: 15841045
[TBL] [Abstract][Full Text] [Related]
10. [Nuclear and cytoplasmic expressions of survivin in glioma and their prognostic value].
Pan Y; Hu WH; Xie D; Wu QL; Liu YH; Xiang J; Wu HX
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(5):325-9. PubMed ID: 17456361
[TBL] [Abstract][Full Text] [Related]
11. [Expression of survivin gene in pancreatic carcinoma].
Liang ZY; Liu TH; Luo YF; Guan J; Wei SZ; Cao JL; Gao J; Cui QC
Zhonghua Bing Li Xue Za Zhi; 2005 Feb; 34(2):67-70. PubMed ID: 15842798
[TBL] [Abstract][Full Text] [Related]
12. Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma.
Kitamura H; Torigoe T; Hirohashi Y; Asanuma H; Inoue R; Nishida S; Tanaka T; Masumori N; Sato N; Tsukamoto T
Virchows Arch; 2013 Jan; 462(1):101-7. PubMed ID: 23179762
[TBL] [Abstract][Full Text] [Related]
13. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker.
Saito T; Arifin MT; Hama S; Kajiwara Y; Sugiyama K; Yamasaki F; Hidaka T; Arita K; Kurisu K
J Neurooncol; 2007 Apr; 82(2):193-8. PubMed ID: 17151933
[TBL] [Abstract][Full Text] [Related]
14. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.
Bria E; Visca P; Novelli F; Casini B; Diodoro MG; Perrone-Donnorso R; Botti C; Sperduti I; Facciolo F; Milella M; Cecere FL; Cognetti F; Mottolese M
Eur J Surg Oncol; 2008 May; 34(5):593-8. PubMed ID: 17693049
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of expression of apoptosis-related proteins and their correlation with HPV, telomerase activity, and apoptotic index in cervical cancer.
Singh A; Sharma H; Salhan S; Gupta SD; Bhatla N; Jain SK; Singh N
Pathobiology; 2004; 71(6):314-22. PubMed ID: 15627842
[TBL] [Abstract][Full Text] [Related]
16. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis.
Sun HC; Qiu ZJ; Liu J; Sun J; Jiang T; Huang KJ; Yao M; Huang C
Int J Oncol; 2007 Jun; 30(6):1359-67. PubMed ID: 17487356
[TBL] [Abstract][Full Text] [Related]
17. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma.
Grabowski P; Kühnel T; Mühr-Wilkenshoff F; Heine B; Stein H; Höpfner M; Germer CT; Scherübl H
Br J Cancer; 2003 Jan; 88(1):115-9. PubMed ID: 12556969
[TBL] [Abstract][Full Text] [Related]
19. Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.
Kim GY; Lim SJ; Kim YW
Mod Pathol; 2011 Oct; 24(10):1336-47. PubMed ID: 21572400
[TBL] [Abstract][Full Text] [Related]
20. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.
Brennan DJ; Rexhepaj E; O'Brien SL; McSherry E; O'Connor DP; Fagan A; Culhane AC; Higgins DG; Jirstrom K; Millikan RC; Landberg G; Duffy MJ; Hewitt SM; Gallagher WM
Clin Cancer Res; 2008 May; 14(9):2681-9. PubMed ID: 18451232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
